Floatz logo

Fosifloxuridine Nafalbenamide

Oesophageal Carcinoma

NuCana plcSmall moleculePhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Oesophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC
Palbociclib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Fosifloxuridine Nafalbenamide is also rated in:

colorectal neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →
colorectal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →